Table 1.
Patient characteristics
| Variable | (N = 156) |
|---|---|
| Age years | |
| Median (range) | 64 (33–81) |
| Gender % (n/N) | |
| Male | 76.9 (120) |
| Female | 23.1 (36) |
| Site of tumour % (n/N) | |
| Lung | 100 (156) |
| Stage % (n/N) | |
| Iib | 4.5 (7) |
| IIIa | 9 (14) |
| IIIb | 12.2 (19) |
| IV | 74.3 (116) |
| Cisplatin dosage (mg/m2) % (n/N) | |
| 75 | 45.5 (71) |
| 80 | 41 (64) |
| 90 | 6.4 (10) |
| 100 | 7.1 (11) |
| Regimen | |
| Cisplatin combined with 2 drugs | 87.4 (152) |
| Cisplatin only | 2.6 (4) |
| Chemotherapy cycles completed % (n/N) | |
| Yes | 83.6 (146) |
| 6 cycles planned | 80.2 (118) |
| 4 cycles planned | 18.2 (28) |
| No* | 6.4 (10) |
*
Five patients attributable to progression and three patients attributable to chemotherapy toxicity.